Ivan Dikić research is dedicated to deciphering the molecular mechanisms of cellular signaling pathways, which have a high relevance to human diseases such as cancer, neurodegenerative disorders and inflammation. Research in the Dikic group is centered around the two major cellular quality control pathways: the ubiquitin system and autophagy. As such they provide protection against rapid aging and various human diseases and are involved in almost all cellular signaling processes. He and his team in Frankfurt try to understand how the ubiquitin labeling is specifically recognized by the respective interaction partners. Further the team was able to discover and characterize new ubiquitin-binding regions in protein molecules. In structural and functional studies they investigated the importance of these protein areas for the regulation of autophagy, DNA repair, inflammatory reactions, cancers, infections, receptor endocytosis and protein degradation. More recently, his group is tracking a novel ubiquitin signal, the so-called "linear ubiquitination," and tries to understand the mechanisms by which this label regulates cellular signal cascades that govern the life or death of a cell.
Ivan Dikić studied human medicine and obtained his medical doctor in Zagreb (Croatia). In 1992, he obtained his PhD in Molecular Biology in the lab of Joseph Schlessinger New York (USA). He moved back to Europe in 1997 to start his own group at the Ludwig Institute for Cancer Research in Uppsala (Sweden). Since 2002, he is a full professor for biochemistry at Goethe University and also leading the Buchmann Institute of Molecular Life Sciences since 2009.
source: lab page